

November 8, 2006

CURRICULUM VITAE

NAME: Charles Erwin Ford, Ph.D. **Title:** Associate Professor of Biostatistics

OFFICE ADDRESS: The University of Texas Health Science Center at Houston
School of Public Health
1200 Herman Pressler St., Room E-827
Houston, Texas 77030
(713) 500-9513; Fax: (713) 500-9530;
Internet: Charles.E.Ford@uth.tmc.edu

EDUCATION:

- 1986 Ph.D., Biostatistics, The University of Texas-Houston School of Public Health
Dissertation: ***Polychotomous Logistic Regression Analysis***
- 1981 M.S., Biostatistics, The University of Texas-Houston School of Public Health
Thesis: ***The Use of a Categorical Model to Examine the Effect of Pre-existing
End-Organ Damage on the Pharmacologic Control of Hypertension***
- 1969 B.S., Mathematics, University of Central Oklahoma

PROFESSIONAL EXPERIENCE & RESEARCH:

Academic:

- 1995- **Associate Professor of Biostatistics**, The University of Texas Health Science
Center at Houston (UTHSC), School of Public Health (UTSPH)
- 1986-95 **Assistant Professor of Biostatistics**, The University of Texas-Houston Health
Science Center, School of Public Health

Service:

- 2003-06 **Abstract Reviewer**, American Heart Association annual scientific meeting.
- 2002-03 **Judge**, National Youth Leadership Forum on Medicine.
- 2000-02 **Member** *SPH Admissions Committee*, representing Disease Control Module
- 1997-99 **Member** *Interfaculty Council*, The University of Texas Health Science Center
- 1995-00 **Co-Director**, *Conference on Career Opportunities in Public Health for
Mathematics and Science Majors*. The Conference goal is to increase the
number of well qualified applicants to graduate programs at the School of
Public Health by informing undergraduate faculty from colleges and
universities in Texas and surrounding states about public health and career
opportunities for their students.
- 1994-00 **Member** *Academic Computing Committee*, UTHSC standing committee.
- 1992-96 **Member**, *Information Resources Steering Team*, UTHSC -- Special standing
UTHSC committee to review information resources and needs at UT-Houston
Health Science Center for strategic planning.
- 1988- **Member**, *Biostatistics Admissions Committee*

Research:

- 2006- **Principal Investigator**, Clinical Trials Center for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): contact award (\$88 million) from the National Heart, Lung, and Blood Institute. Barry R. Davis is the principal investigator at UTSPH. ALLHAT is a large-scale, double-blind, multicenter, clinical trial in 625 centers throughout the United States and Puerto Rico to test the effectiveness of four antihypertensive agents in reducing the incidence of coronary heart disease in 40,000 patients 55 years of age and older with diastolic and/or systolic hypertension. A second, nested clinical trial will test the effectiveness of an HMG-CoA reductase inhibitor in reducing mortality in 20,000 of these patients.
- 2003-2005 **Principal Investigator**, *Preparation of Limited Access Data Sets for the Hypertension Detection and Follow-up Program (HDFP) and the Systolic Hypertension in the Elderly Program (SHEP)*, National Heart, Lung, and Blood Institute (NHLBI), contract N02-HL-3-4 (\$134,749). A limited access data set and supporting documentation for two major NHLBI clinical trials, HDFP and SHEP, was developed and delivered to NHLBI. These data sets and their documentation meet current NHLBI and HIPPA confidentiality and documentation requirements.
- 2001-2003 **Co-Investigator**, *Genetics of Angioedema*, Bristol-Meyer Squibb Company, contract (\$2 million). Principal Investigator: Eric Boerwinkle (UTSPH). Genetic sequencing and genotyping of candidate genes possibly related to the development of angioedema in the treatment of hypertension.
- 1999- **Co-Principal Investigator**, *Genetics of Hypertension Associated Treatments (GenHAT)*, National Heart, Lung, and Blood Institute, R01 grant (\$981,516) funded through the University of Minnesota where the principal investigator is located. Barry Davis is the UTSPH principal investigator. Total grant for the three participating groups is \$4,651,890; Dr. Eric Boerwinkle (UTSPH) was also funded as part of this grant. The group will study genotype-treatment interactions in the treatment of hypertension, using data and DNA samples from the 42,418 participants in ALLHAT (see below).
- 1993-2006 **Co-Investigator**, Clinical Trials Center for the *Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)*: contact award (\$88 million) from the National Heart, Lung, and Blood Institute. Barry R. Davis is the principal investigator at UTSPH. ALLHAT is a large-scale, double-blind, multicenter, clinical trial in 625 centers throughout the United States and Puerto Rico to test the effectiveness of four antihypertensive agents in reducing the incidence of coronary heart disease in 40,000 patients 55 years of age and older with diastolic and/or systolic hypertension. A second, nested clinical trial will test the effectiveness of an HMG-CoA reductase inhibitor in reducing mortality in 20,000 of these patients.
- 1994-1995 **Principal Investigator**, *Renal Cell Carcinoma Incidence in Patients Receiving Antihypertensive Pharmacologic Treatment*, Merck Research Laboratories, \$3,000. Analyses were carried out at the request of Merck scientists on the 6.5-year incidence of renal cell carcinoma (fatal and nonfatal)

among the 10,940 participants in the Hypertension Detection and Follow-up Program (HDFP).

- 1991-1995 **Principal Investigator**, subcontract to *A Prospective Study of Blood Pressure and ESRD*, Johns Hopkins University, R01 grant (\$69,750) funded through the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Data on 159,000 screenees for the Hypertension Detection and Follow-up Program are being compared with data from the Health Care Finance Administration's End-Stage Renal Disease (ESRD) Program database to investigate the relationship between blood pressure and the incidence of ESRD in a prospective, community-based sample of the U.S. ambulatory population.
- 1991-1995 **Co-Director**, *Training Grant for Career Opportunities in Biostatistics and Public Health for Science Majors*, Bureau of Health Professions, U.S. Public Health Service. Summer conferences on career opportunities in biostatistics and public health for science majors were held on three consecutive summers at UTSPH. Conference participants were selected through competitive application from the science and math faculty of undergraduate institutions in Texas and surrounding states. Conference goal is to increase the number of qualified applicants to graduate programs in biometry and biostatistics, particularly the School of Public Health's Biometry Program.
- 1986-1995 **Co-Principal Investigator**, *Extended Analyses in the Hypertension and Detection and Follow-up Program (HDFP) — Risks and Benefits*: R01 grant (\$727,358) from the National Heart, Lung, and Blood Institute. Extended mortality surveillance of the HDFP population through the National Death Index and Social Security Administration. Risk factors for long-term mortality among persons with hypertension are being studied as well as the long-term benefits from effective pharmacologic control of high blood pressure in this cohort of 25,000 participants screened in 14 centers in 1973 to 1974. Mortality follow-up is being extended through 1987.
- 1978-1986 **Biostatistician**, Coordinating Center for Clinical Trials, The University of Texas-Houston School of Public Health. Responsible for data analysis, quality control, monitoring, and reporting of NHLBI funded large-scale, multicenter, cardiovascular clinical trials.
- 1977-1978 **Senior Systems Analyst/Director of Computer Programming**, *Hypertension Detection and Follow-up Program (HDFP)* (NHLBI contract; \$15.9 million) and the *Beta-Blocker Heart Attack Trial (BHAT)* (NHLBI contract; \$4.1 million). These two large-scale, multicenter clinical trials are among the largest clinical trials ever conducted through funding from the NHLBI. The databases for these two studies were composed of hundreds of millions of data items and were efficiently managed and analyzed at the Coordinating Center for Clinical Trials, The University of Texas-Houston School of Public Health.
- 1974-1977 **Senior Systems Analyst/Programmer**, Coordinating Center for Clinical Trials, The University of Texas-Houston School of Public Health. Responsible for the design and implementation of data systems for management and analysis of large-scale, multicenter clinical trials.

- 1971-1974 **Data Systems Programmer/Analyst**, Lockheed Electronics Company, Inc., Houston Aerospace Systems Division. Participated as part of the programming team responsible for the design and implementation of interactive information management systems for the National Aeronautics and Space Administration's (NASA) Crew Procedures and Flight Control Divisions, and provided mathematical and statistical analysis support for the Computational and Analysis Division, National Aeronautics and Space Administration, L. B. Johnson Space Center, Houston, Texas.
- 1969-1971 **Computer Programming Specialist**, United States Army, with service in Vietnam (1970-1971). Developed and maintained the information management system and database for U.S. Army personnel in Vietnam.
- 1969 **Associate Scientist**, Lockheed Electronics Company, Inc., Houston Aerospace Systems Division. Conducted trajectory and orbital error analysis for Apollo Space Program.

Professional Consulting:

- 2006 *BioMarin Pharmaceutical, Inc.*, Novato, CA: Data and Safety Monitoring Board, A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of the Effects of 6R-BH4 (sapropterin dihydrochloride) on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension.
- 2004 *National Institute of Diabetes and Digestive and Kidney Diseases*: Site visit team for the CRIC Data Coordinating Center Chronic Renal Insufficiency Cohort (CRIC), November 4, 2004.
- 2002 *National Institute of Diabetes and Digestive and Kidney Diseases*: Review group for "Polycystic Kidney Disease Clinical Trials Network."
- 2001 *National Institute of Diabetes and Digestive and Kidney Diseases*: Review group for "Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia."
- 2001 *National Institute of Diabetes and Digestive and Kidney Diseases*: Review group for "Technical Support for the NIDDK Epidemiology Coordinating Committee."
- 2000 *Wake Forest University School of Medicine*, Review group for "Selection of Electrocardiogram Reading Center for the Study of Health Outcomes of Weight Loss (SHOW)."
- 1998 *Baylor College of Medicine, Department of Family and Community Medicine*: "Impact of Improved Hypertension Control on Morbidity and Mortality in a Low-Income, African-American Clinic Population."
- 1995 *National Institute of Diabetes and Digestive and Kidney Diseases*: Ad Hoc Review Group for "Epidemiology of Diabetes Interventions and Complications (EDIC) Study — Clinical Coordinating Center and Data Coordinating Center."
- 1994-01 *National Institute of Diabetes and Digestive and Kidney Diseases*: Member External Advisory Committee for "The African-American Study of Kidney Disease and Hypertension (AASK)."

- 1992-94 *National Institute of Diabetes and Digestive and Kidney Diseases: Member External Advisory Committee for "The African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study."*
- 1992-94 *Johns Hopkins University, School of Public Health and Medical School: "Relationship of early and late changes in renal function to end-stage renal disease;" with Gordon Walker, M.D.*
- 1991-92 *University of Nevada Medical School, Reno, Nevada: "Characteristics and possible risk factors associated with chronic fatigue syndrome in Northern Nevada." and "Proposal for clinical center for the Peripheral Arterial Disease (PAD) pilot study to evaluate treatment and prevention strategies for atherosclerotic cardiovascular disease."*
- 1988-93 *Harris County Health Department and Houston City Health Department: "AIDS projections for Harris County and Houston."*
- 1991-91 *National Institute on Aging: Claude Pepper Centers Ad Hoc Review Committee*
- 1990-90 *National Institute of Diabetes and Digestive and Kidney Diseases: Workshop on Kidney Disease and Hypertension in Blacks*
- 1990-90 *National Heart, Lung, and Blood Institute: Workshop on serum cholesterol and CHD in women and the elderly.*
- 1990-90 *MRC/ICRF Clinical Trial Service Unit, Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford, UK (Richard Peto): "Blood pressure, stroke, and coronary heart disease."*
- 1989-90 *Medical College of St. Bartholomew's Hospital, London, England (Malcom Law): "Relationship of serum cholesterol and cancer."*
- 1989-90 *Duke University Medical Center Hospital, Director of Laboratories: "Statistical design of biochemistry research studies of cholesterol and hyperglycemia."*
- 1989-90 *National Heart, Lung, and Blood Institute: Working Group on Renal Disease and Hypertension*
- 1989-89 *Ciba-Geigy Corporation: "Urinary biochemical profile and survival of persons with declining renal function."*
- 1988-90 *The Johns Hopkins Medical Institutions, Welch Center for Prevention, Epidemiology & Clinical Research: "Development of research designs for studying end-stage renal disease incidence and prevention."*
- 1988-88 *University of Nevada Medical School, Reno, Nevada: "Design of biostatistics curriculum for medical students."*
- 1979-81 *Marion Laboratories, Inc., Kansas City, Missouri: "Statistical analysis and data quality assurance for a controlled, double-blind, Phase III clinical trial evaluating the efficacy and safety of a new antidepressant drug: Dothiepin hydrochloride."*

RESEARCH INTERESTS:

Biometry/biostatistics; design, conduct and analysis of multicenter clinical trials; geometry of multivariate analysis; statistical computing; multiple endpoints analysis; longitudinal data analysis; polychotomous logistic regression analysis; chronic diseases; cardiovascular disease, hypertension, end-stage renal disease, diabetes; genetics of hypertension and its pharmacologic treatment.

AWARDS & HONORS:

2002-2003 International and National Honors in Research Award, The University of Texas Health Science Center at Houston, 2003; for ALLHAT which received recognition from the American Heart Association's top 10 research advances for 2002 and for the journal article describing findings in this landmark clinical study which was recognized by the Thomson-ISI Web of Science database as "one of the most cited recent papers in the field of clinical medicine."

American Men & Women of Science, 2000

Outstanding Scholarship Award, The University of Texas Health Science Center at Houston, 1994

Outstanding Achievement in Sponsored Research Award, The University of Texas Health Science Center at Houston, 1994; for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Clinical Trials Center — "Largest Contract Ever Received by UT-Houston"

American Men & Women of Science, 1994

Outstanding Faculty Award, The University of Texas Health Science Center at Houston, 1993

Fellow, American Heart Association Council on Prevention and Epidemiology, 1989

PROFESSIONAL AFFILIATIONS:

American Heart Association Council on Epidemiology, Fellow

American Statistical Association

Biometrics Society

Houston Area Chapter of the American Statistical Association

Institute of Mathematical Statistics

Society for Clinical Trials

Society for Epidemiologic Research

COURSES TAUGHT:

Theory of Multivariate Analysis I and II

Statistical Programming I and II

Statistical Theory of Biostatistics (Mathematical Statistics)

Intermediate Methods of Biostatistics I and II

Math Review (2 week service course given at beginning of each Fall semester)

FREQUENT LECTURES GIVEN IN:

Statistical Methods in Clinical Trials

Epidemiology & Prevention of Cardiovascular Disease

Advanced Epidemiologic Methods

Design of Experiments

Introduction to Program Evaluation

Design & Conduct of Disease Intervention Clinical Trials

TOPICS OF SUPERVISED INDIVIDUAL STUDIES:

Multivariate Analysis

General Linear Models
Statistical Computing & Programming Concepts
Advance Algorithms for Statistical Analyses
Sample Size Algorithms and Computation
Differential & Integral Calculus
Linear Algebraic Analysis
Special Topics in Disease Control
Special Topics in Biostatistics

APPOINTMENTS & COMMITTEE MEMBERSHIP:

- Nominating Committee, The University of Texas-Houston Health Science Center (UTHSC) (2005-2007)
- SPH Admissions Committee (2000-2002)
- Interfaculty Council Subcommittee on Teaching Effectiveness, (1998-1999)
- Endpoints Committee, Antihypertension and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (1996-2002)
- Medical Management Committee, Antihypertension and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (1998-2002)
- Publications Committee, Antihypertension and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (1994-present)
- Ad Hoc committee on Strategic Planning for Information Resources, The University of Texas-Houston Health Science Center (UTHSC), President Low, Chair, (1994) — Review issues and stimulate strategic alternatives regarding the needs of UT-Houston for information resources in the near future.
- Scientific and Educational Programs Committee, Antihypertension and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (1994-2002)
- Quality Control Committee, Antihypertension and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (1994-2002)
- External Advisory Committee for National Institute of Diabetes and Digestive and Kidney Diseases' (NIDDK) African-American Study of Kidney Disease and Hypertension (AASK), (1994-2001)
- External Advisory Committee for NIDDK's African-American Study of Kidney Disease and Hypertension (AASK) Pilot Study, (1992-1994)
- Claude Pepper Centers Ad Hoc Review Committee, National Institute on Aging, (1991)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Workshop on Kidney Disease and Hypertension in Blacks, (1990)
- National Heart, Lung, and Blood Institute (NHLBI): Workshop on serum cholesterol and CHD in women and the elderly, (1990)
- Disease Control Admissions Committee, UTSPH (1988-2003)
- UTSPH Faculty Merit Review Committee, UTSPH (1987)
- Editorial Review and Publications Committee, Hypertension Detection and Follow-up Program (HDFP), (1986-1994)

PUBLICATIONS:

1. Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leidecker-Foster C, Miller MB, Black H, Eckfeldt JH. **Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.** *The Pharmacogenomics J* 2006; (In Press).
2. Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL, for the ALLHAT Collaborative Research Group. **Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** *J Clin Hypertens* 2006; 8:649-656.
3. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leidecker-Foster C, Miller MB, Black H, Eckfeldt JH. **Pharmacogenetic association of the enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) Study.** *Circulation* 2005; 111:3374-3383.
4. Wright JT, Dunn K, Cutler J, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FHH, Margolis K, Papademetriou V, Probstfield JL, Whelton PK, Habib GB, for the ALLHAT Collaborative Research Group. **Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.** *JAMA* 2005; 293:1595-1608.
5. Lusk CM, Bettencourt J, Carroll L, Egan D, Ford C, Kingry C, Johnson J, Sullivan S, Nwachuku C, Probstfield JL. **The ALLHAT Adherence Survival Kit.** *Applied Clinical Trials* 2004; 13:40-48.
6. Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckfeldt J, Black H. **Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses -- A new method for the Genetics of Hypertension Associated Treatment (GenHAT) Study.** *Statistics in Medicine* 2004; 23:2413-2427.
7. Papademetriou V, Piller LB, Ford CE, Gordon D, Hartney TJ, Geraci TS, Reison E, Sumner BM, Wong ND, Nwachuku C, Narayan P, Haywood LJ, Habib G. **Characteristics and lipid distribution of a large, high-risk, hypertensive population: The lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** *J Clin Hypertens* 2003; 5:377-385.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. **Diuretic versus a-blocker as first-step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** *Hypertension* 2003; 42:239-246.
9. Gorham RA, Emery RJ, Ford CE, Cooper SP. **Statistical validation of a commonly used method for personnel dosimetry issuance determinations.** *Health Physics* 2003; 84:260-265.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. **Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** *JAMA* 2002; 288:2981-2997.
11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.

- Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).** *JAMA* 2002; 288:2998-3007.
12. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, for the ALLHAT Collaborative Research Group. **Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** *J Clin Hypertens* 2002; 4:393-404.
 13. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. **Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study.** *The Pharmacogenomics Journal* 2002; 2:309-317.
 14. Cooksley CD, Hwang LY, Ford CE. **HIV and cancer: Community-based analysis of trends and registry linkage.** *J Registry Management* 2001; 28:82-87.
 15. Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro V, Echfeldt J, Hawkins CM, Proschan M, for the ALLHAT Collaborative Research Group. **Baseline characteristics of the 42,448 high risk hypertensives enrolled in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** *Hypertension* 2001; 37:19:27.
 16. Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, parks H, Simpson LM, Nwachuku C, Furberg CD, for the ALLHAT Collaborative Research Group. **Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** *Controlled Clinical Trials* 2001; 22:29-41.
 17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. **Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** *JAMA* 2000;283:1967-1975.
 18. Djojonegoro BM, Aday LA, Williams AF, Ford CE. **Area income as a predictor of preventable hospitalizations in the Harris County Hospital District, Houston.** *Texas Medicine* 2000; 96:58:62.
 19. Cooksley CD, Hwang LY, Waller DK, Ford CE. **HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data.** *International Journal of STD & AIDS* 1999; 10: 795-802.
 20. Proschan M, Davis B, Cutler J Ford C, Furberg C, Grimm R, and Oparil S, for the ALLHAT Research Group. **ALLHAT and calcium channel blockers.** *American Journal of Hypertension* 1997;10:142-143. (Letter to the Editor)
 21. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm R, LaRosa J, Whelton PK, Perry HM, Alderman M, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. **Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** *American Journal of Hypertension* 1996; 9:342-360.

22. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. **Blood pressure and incidence of end-stage renal disease in men.** *New England Journal of Medicine* 1996; 334:13-18.
23. Walker WG, Ford C. **At risk nephrons and the decline in renal function in response to treatment of hypertension.** *Transactions of the American Clinical and Climatological Association* 1995; 107:134-145.
24. Tyroler HA, Ford CE. **Serum cholesterol and coronary heart disease risk in female and older hypertensives: the experience under usual community care in the HDFP.** *Ann Epidemiol* 1992; 2:155-160.
25. Walker WG, Ford CE, Cutler JA, Shulman NB, for the HDFP Research Group. **Change in renal function during treatment in the Hypertension Detection and Follow-up Program (HDFP).** *Am J Hyperten* 1992; 5:58a.
26. Stamler R, Ford CE, Stamler J. **Why do lean hypertensives have higher mortality rates than other hypertensives? Findings from the Hypertension Detection and Follow-up Program.** *Hypertension* 1991; 17:553-564.
27. Cooper SP, Ford CE, Hardy RJ, Davis BR, Hawkins CM, Labarthe DR. **Letter to the Editor regarding "Goals of antihypertensive therapy: is there a point beyond which pressure reduction is dangerous?"** *American Journal of Hypertension* 1990; 3:733-734.
28. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. **The prognostic value of serum creatinine and the effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program.** *Hypertension* 1989; 13(Suppl 1):80-93.
29. HDFP Cooperative Group. **Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program.** *JAMA* 1988; 259:2113-2122.
30. Schneider KA, Heyden S, Ford C. **Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD. Evidence from the HDFP.** *Nefron* 1987; 47(Suppl 1):104-107.
31. Ford CE, Langford HG, Palmer M. **Recruitment in the Hypertension Detection and Follow-up Program.** *Controlled Clinical Trials* 1987; 8:54S-67S.
32. Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM. **The HDFP design, methods, and baseline characteristics and blood pressure response of the study population.** *Progress in Cardiovascular Disease* 1986; 29(Suppl 1):11-28.
33. HDFP Cooperative Group. **Implications of the HDFP.** *Progress in Cardiovascular Disease* 1986; 29(Suppl 1):3-10.
34. HDFP Cooperative Group. **Results and implications of the Hypertension Detection and Follow-up Program.** *Progress in Cardiovascular Disease* 1986; 29(Suppl 1):1-124.
35. Curb JD, Ford C, Pressel S, Palmer M, Babcock C, Hawkins CM. **Ascertaining vital status through the National Death Index and the Social Security Administration.** *Am J Epidemiol* 1985; 121:754-766.
36. Maxwell MH, Ford CE. **Cardiovascular morbidity and mortality in HDFP patients 50-69 years old at entry.** *J of Cardiovascular Pharmacology* 1985; 7(Suppl 2):5-9.

37. HDFP Cooperative Group. **Mortality findings for stepped-care and referred-care participants in the HDFP, stratified by other risk factors.** *Preventive Medicine* 1985; 14:312-335.
38. HDFP Cooperative Group. **Five-year findings of the HDFP. Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy.** *Hypertension* 1985; 7:105-112.
39. HDFP Cooperative Group. **The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience.** *Circulation* 1984; 70:996-1003.
40. HDFP Cooperative Group. **Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. Five-year findings of the HDFP.** *Hypertension* 1984; 6(Suppl I):198-206.
41. HDFP Cooperative Group. **The Hypertension Detection and Follow-up Program. Baseline characteristics of the enumerated, screened, and hypertensive participants.** *Hypertension* 1983; 5(Suppl IV):1-200.
42. Curb JD, Ford C, Hawkins CM, Smith EO, Zimbaldi N, Carter B, Cooper C. **The Coordinating Center in a clinical trial: the HDFP.** *Controlled Clinical Trials* 1983; 4:171-186.
43. Curb JD, Hawkins CM, Ford C. **Should mild hypertension be treated.** (Letter) *N Engl J Med* 1982; 307:1522-1523.
44. HDFP Cooperative Group. **Five-year findings of the Hypertension Detection and Follow-up Program. III. Reduction in stroke incidence among persons with high blood pressure.** *JAMA* 1982; 247:633-638.

Books, Chapters, Miscellaneous

Davis BR, Ford CE. **The Hypertension Detection and Follow-up Program**, in *Clinical Trials in Hypertension*, 2001; pp:27-60, Henry R. Black (Ed.), Marcel Dekker, New York, New York.

Davis BR, Ford CE. **Annotated Bibliography of Epidemiological Methods of Cardiovascular Research. Chapter 12: Blood Pressure.** Committee on Criteria and Methods of the Council on Epidemiology, American Heart Association, 1994.

ABSTRACTS AND PRESENTATIONS:

Alderman MH, Piller LB, Ford CE, Cushman W, Calhoun D, Davis BR, Eckfeldt J, Einhorn P, Franklin S, Furberg C, Ong S, Oparil S, Papademetriou V, Probstfield J. **The occurrence and clinical impact of hypo- and hyperkalemia in ALLHAT.** (Presented by Jeff Probstfield at the European Society of Cardiology, September 7, 2005, Stockholm, Sweden.)

Haywood J, Ford CE, Crow RS, Davis BR, Einhorn PT, Williard A, Massie B. **Atrial Fibrillation in ALLHAT.**(Presented by Julian Haywood at the International Society on Hypertension in Blacks Meeting, June 13-16, 2004, Detroit, Michigan.) Abstract: *Ethnicity and Disease* 2004; 14:??-??.

- Cushman WC, Ford CE, Einhorn P, Wright JT, Preston RA, Davis BR, Basile JN. **Blood pressure control by randomized drug group in ALLHAT.** (Presented by Bill Cushman at the 19th Annual Meeting of the American Society of Hypertension, May 18-22, 2004, New York, NY.) Abstract: *Am J Hypertension* 2004; 17:S30.
- Haywood LJ, Ford CE, Crow RS, Davis BR, Einhorn PT, Williard A, Massie B. **Atrial fibrillation at baseline and during follow-up in ALLHAT.** (Presented by C Ford at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida.) Abstract: *Circulation* 2003; 108(Suppl IV):IV-371.
- Ford CE. **Blood pressure control: Success of a structured treatment program.** (Presented at a special UT Health Science Center at Houston symposium held in the School of Public Health Auditorium, September 19, 2003.)
- Ford CE, Margolis KL, Piller L, Cushman WC, Wright JT, Colon PJ, for the ALLHAT Collaborative Research Group. **Blood pressure control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** (Presented by CE Ford at the 15th Scientific Meeting of the Inter-American Society of Hypertension, April 27-30, 2003, San Antonio, Texas.)
- Ford CE. **ALLHAT Results: Diuretic best for treating hypertension.** (Presented at the 2003 SPH Faculty and Student Research Day, The University of Texas Health Science Center at Houston, School of Public Health, March 21, 2003.)
- Davis BR, Ford CE, Boerwinkle E, Arnett D, Eckfeldt J, Black H. **Gene-drug interactions in the context of an active-controlled trial.** (Presented by BR Davis at the 2002 Joint Statistical Meetings of the American Statistical Association, the International Biometric Society (ENAR and WNAR), the Institute of Mathematical Statistics, and the Statistical Society of Canada, August 13, 2002, New York, New York.)
- Ford C. **Conducting clinical trials in private practices: What works and what doesn't.** (Presented by CE Ford at the 22nd Annual Meeting of the Society for Clinical Trials, May 20-23, 2001, Denver, Colorado.) Abstract: *Controlled Clinical Trials* 2001; 22:17S.
- Margolis K, Piller L, Lewis C, Goff D, Cushman W, Wright J, Colon P, Ford C. **Blood pressure control in Hispanic participants in ALLHAT.** (Presented by K Margolis at the American Heart Association Conference on Cardiovascular Disease Epidemiology and Prevention, March 2, 2001, San Antonio, Texas.) Abstract: *Circulation* 2001; 103:1348.
- Ford CE, Wright JT. **Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone, with additional data on Hispanics.** (Presented by CE Ford at the Fifth Meeting of the ALLHAT Investigators, September 16, 2000, Orlando, Florida.)
- Colon PJ, Wright JT, Ford CE, Cuttler JA, for the ALLHAT Collaborative Research Group. **Cardiovascular disease rates in Hispanic and Caribbean hypertensives receiving doxazosin and chlorthalidone in the ALLHAT.** (Presented by P. Colon at the Joint Meeting of the International Society for Hypertension in Blacks and the 15th Annual Interdisciplinary Conference on Hypertension and Related Risk Factors in Ethnic Populations, July 15-18, 2000, Las Croabas, Puerto Rico.) Abstract: *Ethnicity and Disease* 2000; 10:315-316.
- Bettencourt J, Ford CE. **Differences in adherence patterns of ALLHAT participants.** (Presented by J Bettencourt at the 21st Annual Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000.) Abstract: *Controlled Clinical Trials* 2000; 21:105S-106S.

Kimmel B, Ford C, Piller L, Pressel S. **Importance of assessing vital status of participants and collecting endpoint data in clinical trials (ALLHAT study).** (Presented by B. Kimmel at the 1999 UT-HHSC Research Day, October 8, 1999, Houston, Texas.)

Haywood J, Crow R, Ford C, Davis B, for the ALLHAT Research Group. **Atrial fibrillation in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial at baseline.** (Presented by J. Haywood at the International Society on Hypertension in Blacks (ISHIB), July 11-13, 1999, Toronto, Canada. Abstract: pending.)

Ford CE. **From where do all those health statistics come.** (Presented at the 7th Annual Summer Conference on Opportunities in Public Health, May 26-28, 1999, in Houston, Texas.)

Ford CE. **The Silent Killer - Hypertension; The Disease Control Module at UT-HSPH.** (Presented at the 7th Annual Summer Conference on Opportunities in Public Health, May 26-28, 1999, in Houston, Texas.)

Margolis KL, Cushman WC, Wright JT, Grimm RH, Ford CE, Cutler JA for the ALLHAT Research Group. **Racial differences in blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.** (Presented by KL Margolis at the 22nd Annual Meeting of the Society for General Internal Medicine, San Francisco, California, April 30, 1999.)

Davis BR, Ford CE, Boerwinkle E, Atwood L, Arnett D. **Design and analysis considerations for assessing gene-treatment interactions in a clinical trial.** (Presented by BR Davis at the 1998 Joint Statistical Meetings, August 9, 1998, in Dallas, Texas.)

Nwachuku CE, Cutler J, Payne GH, Proschan MA, Ford CE, Davis BR, Pressel S, Hawkins CM, for the ALLHAT Research Group. **Regional differences in attainment of goal blood pressure (BP) among treated hypertensives in the United States.** (Presented by CE Nwachuku at the 16th Meeting of the International Society of Hypertension (ISH), June 1998, Amsterdam, Netherlands.) Abstract: *J Hypertension* 1998; 16(Suppl 2):97.

Pressel S, Morvillo C, Kimmel B, Davis B, Ford C, Egan D. **Patient recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** (Presented by S Pressel at the 19th Annual Meeting of the Society for Clinical Trials, May 17-20, 1998 Atlanta, Georgia.) Abstract: *Controlled Clinical Trials* 1998; 19:46S-46S.

Nwachuku CE, Probstfield JL, Ford CE, Payne GH, Grimm RH for the ALLHAT Research Group. **Visit (Vad) and medication (Mad) adherence in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Effect of age and other factors.** (Presented by CE Ford at the 13th Scientific Meeting of the American Society of Hypertension, May 13-16, 1998, New York, NY.) Abstract: *Am J Hypertension* 1998; 11:??A.

Cushman WC, Black HR, Probstfield JL, Holland JJ, Hamilton BP, Margolis K, Nwachuku CE, Payne GH, Ford CE for the ALLHAT Research Group. **Blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** (Presented by WC Cushman at the 13th Scientific Meeting of the American Society of Hypertension, May 13-16, 1998, New York, NY.) Abstract: *Am J Hypertension* 1998; 11:17A.

Cooksley CD, Hwang LY, Waller K, Ford CE. **HIV-related malignancies: A community based study using a linkage of cancer registry and HIV registry data.** (Presented by CD Cooksley at the Second National AIDS Malignancy Conference, April 6-8, 1998,

Bethesda, Maryland.) Abstract: *J of Acquired Immune Syndrome and Human Retro Virology*

Davis BR, Hawkins CM, Cutler JA, Payne G, Ford CE, Pressel S, Gordon D, Nwachuku C, Wright J, Cushman W, Grimm R for the ALLHAT Research Group. **ALLHAT: The largest clinical trial in hypertension ever undertaken.** (Presented by BR Davis at the 6th International Symposium on Hypertension in the Community: Screening, Investigation, and Therapy, February 8-11, 1998, Geneva, Switzerland.)

Grimm RH Jr, Davis BR, Ford C, Alderman MH, Black HR, Cushman WC, DeQuattro V, Papademetriou. **The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): The largest clinical trial in hypertension ever undertaken.** (Presented by RH Grimm at the 70th Scientific Sessions of the American Heart Association, November 9-12, 1997, Orlando, Florida.) Abstract: *Circulation* 1997; 96:1-278.

Davis BR, Proschan M, Ford CE, for the ALLHAT Research Group. **Statistical issues in a large, simple trial of antihypertensive and lipid-lowering treatments.** (Presented by BR Davis at the American Statistical Association Meeting; Chicago, IL; August 4-18, 1996.)

Davis B, Proschan M, Ford CE, for the ALLHAT Research Group. **Statistical design considerations for a large, simple trial of antihypertensive and lipid lowering treatments.** (Presented by B. Davis at the International Biometric Conference; Amsterdam, Netherlands; July 1-5, 1996.)

Ford CE. **The Silent Killer - High Blood Pressure: Evolution of a Public Health Problem.** (Presented at the 4th Annual Summer Conference on Opportunities in Public Health, May 28-31, 1996, in Houston, Texas.)

Harrist RB, Ford CE. **Opportunities in Biostatistics and Public Health for Science Majors.** (Presented by C.E. Ford at the 1995 Joint Statistical Meetings, August 15, 1995, in Orlando, Florida.)

Ford CE. **Biometric applications in public health.** (Presented at the 1995 Conference on Career Opportunities in Biostatistics and Public Health for Science Majors at St. Mary's University, May 19, 1995 in San Antonio, Texas.)

Pressel S, Egan D, Ford CE, Walsh S, Miertschin N. **Selection of clinical sites for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** (Presented by S. Pressel at the 16th Annual Meeting of the Society for Clinical Trials, April 30 - May 3, 1995, Seattle, Washington.) Abstract: *Controlled Clinical Trials* 1995; 16:106S.

Davis BR, Cutler JA, Gordon D, Furberg C, Wright J, Cushman W, Grimm R, LaRosa J, Whelton P, Manolio T, Perry HM, Alderman M, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black H, Hawkins CM for The ALLHAT Research Group. **Rationale and Design of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).** (Presented by B.R. Davis at the 35th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, March 1995.)

Walker WG, Ford CE, Cutler JA, Shulman NB. **Change in Renal Function During Treatment in the Hypertension Detection and Follow-up Program (HDFP).** (Presented by W.G. Walker at the Annual Meeting of the American Society of Nephrology, October, 1994.)

Davis BR, Moyé LA, Ford CE, Wun CC. **Beyond traditional stochastic curtailment.** (Presented by B. R. Davis at the International Biometric Conference (IBC), August, 1994, in Hamilton, Ontario, Canada.)

- Davis BR, Moyé LA, Ford CE, Wun CC. **Stochastically curtailing several types of tests.** (Presented by *B. R. Davis* at the Eastern North American Region (ENAR) of the Biometric Society Spring Meeting, April 10-13, 1994, Cleveland, Ohio.)
- Klag MJ, Whelton PK, Neaton JD, Randall B, Ford CE, Brancati FL, Shulman N, Stamler J. **Race and Incidence of ESRD: A Prospective Study.** (Presented by *M. J. Klag* at the 34th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, March 16-19, 1994, in Tampa, Florida.)
- Klag MJ, Whelton PK, Neaton JD, Randall B, Ford CE, Brancati FL, Shulman N, Stamler J. **Blood pressure and incidence of ESRD in men: a prospective study.** (Presented by *M. J. Klag* at the 34th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, March 16-19, 1994, in Tampa, Florida.)
- Walker WG, Ford CE, Cutler JA, Shulman NB. **Change in Renal Function During Treatment in the Hypertension Detection and Follow-up Program (HDFP).** (Presented by *W.G. Walker* at the 14th Scientific Meeting of the International Society of Hypertension, June 14-19, 1992, in Madrid, Spain.) Abstract: *Journal of Hypertension* 1992; 5:58a.
- Ford CE. **The effect of antihypertensive drug treatment on combined morbidity and mortality in blacks and whites.** (Presented by *C.E. Ford* at the 7th International Interdisciplinary Conference on Hypertension in Blacks, May 28, 1992, in Atlanta, Georgia.)
- Ford CE, Davis BR, Hawkins CM, Stamler J, Langford HG, Daugherty SA, Borhani NO, Curb JD, Payne GH, Remington RD. **The effect of treatment on combined trial endpoints in the Hypertension Detection and Follow-up Program (HDFP).** (Presented by *C.E. Ford* at the 31st Annual Conference on Cardiovascular Disease Epidemiology, March 14, 1991, in Orlando, Florida.) Abstract: *Circulation* 1991; 83: 716.
- Curb JD, Pressel S, Daugherty S, Schneider K, Payne G, Ford C. **The relationship of white blood cell count to total and coronary heart disease mortality.** (Presented by *Sara Pressel* at the 63rd Scientific Sessions of the American Heart Association, November 1990, in Dallas, Texas.) Abstract: *Circulation* 1990; 82(Suppl III): III-616.
- Stamler R, Ford CE, Stamler J. **Why do lean hypertensives have higher mortality rates than average weight hypertensives? Findings from the Hypertension Detection and Follow-up Program.** (Presented by *Rose Stamler* at the 63rd Scientific Sessions of the American Heart Association, November 1990, in Dallas, Texas.) Abstract: *Circulation* 1990; 82(Suppl III): III-554.
- Moorman PG, Ford CE, Tyroler HA. **Educational level and all-cause mortality in the HDFP trial and Post-Trial Surveillance Study (PTSS).** (Presented by *P.G. Moorman* at the 13th Scientific Meeting of the International Society of Hypertension, June 1990, in Montreal, Canada.)
- Davis BR, Ford CE, Mahboob S. **Short-term projections of AIDS incidence in Texas.** (Presented by *Barry Davis* at the 1990 Conference of Texas Statisticians, March 23, 1990, Houston, Texas.)
- Ford CE, Shulman NB. **Prevalence, incidence, prognostic value, and treatment implications of renal disease in a hypertensive population.** (Presented by *C.E. Ford* at the NHLBI Workshop on Antihypertensive Drug Treatment: The Benefits, Costs, and Choices, Bethesda, Maryland, June 11-12, 1987.)

HDFP Cooperative Group. **Eight-year follow-up of participants in the HDFP: Persistence of reduction in blood pressure and mortality in a treated hypertensive population.**

(Presented by C.E. Ford at 52nd Annual Scientific Assembly of the American College of Chest Physicians, San Francisco, California, September 25, 1986.) Abstract: *Chest* 1986; 89:496S. (Also presented by N.O. Borhani at the 11th Congress of the International Society of Hypertension, Heidelberg, Federal Republic of Germany, September 1986.)

Schneider KA, Heyden S, Ford CE. **Failure to reduce cholesterol as explanation for limited efficacy of antihypertensive treatment in the reduction of CHD. Evidence from the HDFP.**

(Presented by K.A. Schneider at the Satellite Symposium to the 11th Congress of the International Society of Hypertension, Titisee, Federal Republic of Germany, September 1986.)

Daugherty SA, Curb JD, Ford CE, Hawkins CM, Langford HG, Pressel S, Taylor JO. **Eight-year follow-up of participants in the HDFP. Persistence in the reduction in blood pressure and mortality in a treated hypertensive population.**

(Presented by S.A. Daugherty at the 25th Conference of the AHA Council of Epidemiology, Tucson, Arizona, March 7, 1985.)

Langford HG, Ford CE, Blaufox MD. **Is hypertension worse in blacks? Comparison of creatinine levels at equal blood pressures; effect of potassium.**

(Presented by H.G. Langford at the 17th Annual Meeting of the American Society of Nephrology, New Orleans, January 31, 1985.)

Maxwell MH, Ford CE. **Cardiovascular morbidity and mortality in HDFP patients 50-69 years old at entry.**

(Presented by M.H. Maxwell at Satellite Symposium on Cardiovascular Morbidity and Large Arteries in Hypertension, Paris, France, June 1984.)

Curb JD, Palmer M, Pressel S, Ford CE, Zimbaldi N, Babcock C, Jennings P, Hawkins CM.

Ascertaining vital status through the National Death Index and the Social Security Administration.

(Presented by J.D. Curb at the 4th Annual Meeting of the Society for Clinical Trials, St. Louis, Missouri, May 8, 1983.) Abstract: *Controlled Clinical Trials* 1983; 4:154.

Curb JD, Hawkins CM, Smith EO, Zimbaldi N, Ford CE, Carter B, Cooper C. **The**

Coordinating Center in a clinical trial.

(Presented by C.E. Ford at the 2nd Annual Meeting of the Society for Clinical Trials, San Francisco, California, May 12, 1981.)

Abstract: *Controlled Clinical Trials* 1981; 2:83.

Blaufox MD, Langford HG, Ford CE. **End-organ damage in hypertension and medication requirements for control of blood pressure.**

(Presented by M.D. Blaufox at the 52nd Scientific Sessions of the American Heart Association, Anaheim, California, November 1979.)

Ford CE. **Monitoring clinical trial study data acquisition by means of an interactive information management system.**

(Presented by C.E. Ford at the Fourth Annual Meeting of Personnel Involved in Coordinating Collaborative Clinical Trials, Chapel Hill, North Carolina, May 19-20, 1977.)